LLY vs. JNJ, ABBV, MRK, PFE, BMY, ZTS, RPRX, CORT, JAZZ, and PRGO
Should you be buying Eli Lilly and Company stock or one of its competitors? The main competitors of Eli Lilly and Company include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry.
Eli Lilly and Company vs.
Eli Lilly and Company (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, community ranking, dividends, risk, institutional ownership, media sentiment and analyst recommendations.
Eli Lilly and Company received 99 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 70.62% of users gave Eli Lilly and Company an outperform vote while only 64.81% of users gave Johnson & Johnson an outperform vote.
Eli Lilly and Company has a net margin of 23.51% compared to Johnson & Johnson's net margin of 18.20%. Eli Lilly and Company's return on equity of 85.24% beat Johnson & Johnson's return on equity.
Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.7%. Johnson & Johnson pays an annual dividend of $5.20 per share and has a dividend yield of 3.3%. Eli Lilly and Company pays out 51.2% of its earnings in the form of a dividend. Johnson & Johnson pays out 57.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and Company has raised its dividend for 11 consecutive years and Johnson & Johnson has raised its dividend for 64 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Eli Lilly and Company currently has a consensus price target of $1,000.32, suggesting a potential upside of 11.17%. Johnson & Johnson has a consensus price target of $171.82, suggesting a potential upside of 9.92%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, equities analysts plainly believe Eli Lilly and Company is more favorable than Johnson & Johnson.
In the previous week, Eli Lilly and Company had 34 more articles in the media than Johnson & Johnson. MarketBeat recorded 123 mentions for Eli Lilly and Company and 89 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.89 beat Eli Lilly and Company's score of 0.82 indicating that Johnson & Johnson is being referred to more favorably in the news media.
Johnson & Johnson has higher revenue and earnings than Eli Lilly and Company. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Eli Lilly and Company has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.
Summary
Eli Lilly and Company beats Johnson & Johnson on 15 of the 22 factors compared between the two stocks.
Get Eli Lilly and Company News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eli Lilly and Company Competitors List
Related Companies and Tools
This page (NYSE:LLY) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy LLY Stock Free LLY Stock Alerts